S1 Plus Anlotinib in Treating Patients With Refractory or Relapsed Small-cell Lung Cancer An One-arm, Phase Ⅱ, Multi-center Clinical Study (SALTER TRIAL)
Latest Information Update: 18 Oct 2024
At a glance
- Drugs Catequentinib (Primary) ; Gimeracil/oteracil/tegafur (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- Acronyms SALTER
Most Recent Events
- 27 Sep 2024 Results (n=71) assessing the efficacy and safety of anlotinib combination with oral fluoropyrimidine S1 in patients with Refractory or Relapsed SCLC published in the BMC Cancer.
- 22 Feb 2023 Status changed from recruiting to completed.
- 21 Sep 2021 Results (n=71; Between March 2019 to June 2020) assessing the efficacy and safety of anlotinib combination with oral fluoropyrimidine S1 in patients with Refractory or Relapsed small cell lung cancer, presented at the 46th European Society for Medical Oncology Congress.